I

Incyte

Biopharmaceutical company pursuing drug discovery.

Director – Market Insights & Forecasting

Corporate StrategyUpdated on Nov 10
Full-timeChadds Ford Township, PA, USANo salary listedIn-person

About the Job

Requirements

  • A bachelor's degree in business, scientific, quantitative, technical, or a related discipline is required.
  • Eight to 10+ years of pharmaceutical or biotechnology experience in forecasting, market insights, commercial analytics, strategic planning, launch planning, pipeline transition, or decision support.
  • Demonstrated experience translating forecast assumptions, market research, competitive intelligence, clinical or regulatory milestones, and commercial inputs into business implications and planning recommendations.
  • Strong understanding of pharmaceutical commercialization planning, including patient flow, epidemiology, market sizing, forecast assumptions, scenario planning, access considerations, competitive dynamics, and launch-readiness planning.
  • Experience supporting strategic planning, long-range planning, launch planning, forecast reviews, or cross-functional commercial planning processes.
  • Strong analytical capability, including experience with forecast models, dashboard requirements, data visualization, Excel, PowerPoint, and business intelligence tools such as Power BI.
  • Experience and extensive knowledge of medical and pharmacy claims data and longitudinal patient data, such as IQVIA LAAD and NPA.
  • Ability to partner across global and U.S. teams, clarify decision rights, document assumptions, manage planning timelines, and translate early forecast inputs into U.S. commercial planning outputs.
  • Demonstrated ability to operate independently in ambiguous, cross-functional environments with multiple stakeholders, evolving timelines, and high senior-leadership visibility.
  • Ability to synthesize complex qualitative and quantitative information into clear recommendations.

Responsibilities

  • Lead U.S. forecast transition and launch-readiness planning for assets approaching commercialization, particularly products expected to enter U.S. commercial planning windows within approximately two years of launch.
  • Partner with global forecasting teams to understand early-stage forecast assumptions, market models, epidemiology, patient flow, competitive context, evidence expectations, and key uncertainties.
  • Translate global forecast inputs into U.S.-specific commercial planning assumptions, including market size, patient opportunity, treatment flow, adoption drivers, access considerations, competitive dynamics, launch timing, and scenario ranges.
  • Support the Senior Director, Market Insights & Forecasting in developing U.S. forecast assumptions, strategic planning inputs, scenario framing, launch-readiness narratives, risk and opportunity assessments, and senior leadership materials.
  • Coordinate U.S. strategic planning timelines, deliverables, assumption-gathering processes, cross-functional inputs, review meetings, and consolidated planning materials for near-launch assets.
  • Develop and maintain structured handoff processes between global early-stage forecasting and U.S. commercial planning to ensure clear ownership, assumption traceability, documentation, and decision rights.
  • Partner with the Director, Analytics & Decision Support to develop launch-readiness dashboards, planning trackers, forecast comparison views, assumption logs, milestone trackers, and source-of-truth reporting outputs.
  • Partner with Data/Technology, BIS, Finance, and analytics stakeholders to define reporting requirements, support automation of recurring launch-readiness views, integrate planning inputs, and create scalable reporting structures for assets moving toward commercialization.
  • Synthesize primary research, secondary data, competitive intelligence, global assumptions, market access inputs, Medical perspective, and U.S. commercial feedback into planning implications and recommended actions.
  • Support executive-ready materials for strategic planning, launch planning, investment prioritization, forecast reviews, business updates, and cross-functional leadership discussions.
  • Track external and internal signals that may affect U.S. commercialization assumptions, including clinical readouts, regulatory milestones, guideline updates, competitive events, access dynamics, customer feedback, and market structure changes.
  • Ensure launch-readiness forecasting, planning, and reporting activities comply with applicable privacy, legal, regulatory, procurement, finance, and pharmaceutical industry requirements.
  • Provide planning discipline, operating cadence, documentation standards, and cross-functional coordination for U.S. launch-readiness forecasting and strategic planning activities.
  • Lead through influence across matrixed partners, global teams, vendors, analytics resources, and U.S. stakeholders to deliver forecast transition, planning, and reporting outputs.
  • Build cross-coverage between forecasting and analytics by translating near-launch forecast assumptions into dashboard requirements, scalable reporting structures, and executive-ready performance views.
  • Maintain assumption logs, planning calendars, launch-readiness trackers, scenario documentation, and decision-support materials to support continuity across strategic planning cycles.
  • Influence stakeholders through structured problem solving, commercial judgment, analytical credibility, executive communication, and disciplined follow-through.

Desired Qualifications

  • An advanced degree is preferred; the posting does not specify a particular degree type or field.
  • Experience with pharmaceutical data sources such as claims, specialty pharmacy data, syndicated data, market research outputs, patient-level or longitudinal data, internal finance or demand data, and public-company disclosures.
  • Strong communication, presentation, stakeholder management, and project leadership skills.

About the Company

Incyte

Biopharmaceutical company pursuing drug discovery.

Incyte develops and sells medicines by discovering and developing new drugs, focusing on diseases in inflammation, autoimmunity, and blood cancers. Its core product, Jakafi (ruxolitinib), is a JAK1/2 inhibitor approved to treat a rare blood cancer and works by blocking JAK enzymes to reduce abnormal blood cell growth. The company also expands its pipeline through research collaborations, partnerships, and acquisitions, such as the 2024 purchase of Escient Pharmaceuticals to strengthen its inflammation and autoimmune portfolio. Unlike some competitors that rely mainly on internal programs, Incyte combines in-house discovery with external collaborations and strategic deals to grow its drug candidates from early research to approved therapies. The goal is to deliver medicines that help patients with serious diseases by building a diverse, clinically validated portfolio of treatments through internal efforts and partnerships.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Wilmington, DE
Founded
1991

Recently Posted Jobs

Explore more opportunities at Incyte

See more jobs